Neuralink co-founder Max Hodak's Science Corp wins EU approval for Prima, a bionic eye that treats age-related macular degeneration using an implant and glasses
Decision will allow Science Corp to treat patients with retina implants in coming months — A US start-up has received …
Context & Ripple Effects
Science Corp had already reported that its retinal implant could enable some blind participants to read, play cards and recognize faces; a later study of the PRIMA implant-and-glasses system reported vision restoration in some people. The EU decision moves that work from reported study outcomes toward authorized patient treatment.
The company had also raised capital explicitly to commercialize an implant for blindness, including a $230M financing reported in March. Approval makes clinical rollout, rather than device development alone, the immediate test of that commercialization effort.
First-order effects
- Science Corp can begin treating eligible patients in the EU with Prima in the coming months, shifting the company into a clinical-delivery phase for its retinal implant and glasses system.
- Patients with age-related macular degeneration gain access to an authorized implant-based treatment option through providers able to deliver the procedure and supporting glasses.
Second-order effects
- Science Corp must turn authorization into repeatable implantation, patient selection and follow-up workflows; its execution on those steps will now matter alongside the device results previously reported.
- Other developers of vision-restoration and implantable neurotechnology face a clearer commercial benchmark: an EU-authorized product rather than a research-stage demonstration.
Third-order effects
- If more implantable vision systems progress from studies to authorization, competition in neurotechnology will increasingly hinge on clinical deployment capabilities and regulatory evidence, not only on prototype performance.
- The decision suggests a path by which targeted sensory-restoration implants can become a distinct commercial segment within the broader brain-computer-interface field, though adoption will depend on real-world treatment outcomes.
The trend: Implantable neurotechnology is moving from proof-of-concept studies toward regulated, disease-specific clinical products.